Our studies testing another combination immunotherapy for CRC MSS highlight the influence of individual tumors on immune responses, as seen in distinct GrB+ TEM CD8+ versus CD4+TNFα+ driven responses to another tumor (CRC H,I; Figure 7C). This evidence concerns the gene CD8A and neoplasm.